Search for a trial

A Study to Evaluate the Relative Bioavailability and Effect of Food on Two Formulations of the MK-3682A Fixed-Dose Combination Tablets (MK-3682/MK-5172/MK-8742, 300 mg/ 100 mg/50 mg) in Healthy Adult Subjects.

Primary Objective: - to evaluate the pharmacokinetic (PK) parameters (AUC0-t, AUC0-inf, Cmax, C24hr, Tmax, and apparent t*) of MK-3682 and its circulating metabolites (IDX20664 and IDX23267), MK-5172, and MK-8742 following administration of two…

Palatability testing of a new paediatric formulation of valacyclovir for the prophylaxis and treatment of VZV and HSV infections in children - VALID 0

PrimaryTo determine whether the palatability of a newly developed formulation of valacyclovir is non-inferior to administration of crushed and suspended tablets in children, is the primary objective of the second phase of the trial.The primary…

A phase IV, randomized, open label, cross-over, intervention trial to investigate the effect of the switch of protease inhibitors to raltegravir on endothelial function, chronic inflammation, immune activation and HIV replication below 50 copies/ml

1. To assess the effect of the switch from protease inhibitors to raltegravir on endothelial function. 2. To assess the effect of the intervention mentioned above on markers of endothelial function; immune activation; chronic inflammation; and, on…

Bioequivalence study in healthy volunteers of a new paediatric formulation of valacyclovir used for prophylaxis and treatment of VZV and HSV infections in children, phase I (VALID I)

In this trial will be investigated if a new formulation of valacyclovir, e.g. oral solution, is bioequivalent to valacyclovir tablets. This comparison will be made by determining pharmacokinetic parameters (AUC0-*, Cmax, and tmax) of both…

Bioequivalence of Crushed Stribild with a normal breakfast or with drip feed compared to the whole tablet.

Primary objective:To assess the bioequivalence of single dose STB after administration of standardized breakfast followed by a whole tablet (reference) and a crushed and suspended tablet (intervention I).To assess the bioequivalence of single dose…

An Open-Label, Single Dose, 4-Period, 4-Way Randomized Crossover Study to Evaluate the Pharmacokinetics of Preliminary Market Formulations of MK-8408 in Healthy Adult Subjects.

Primary:1. To assess the pharmacokinetic profiles following single dose administration of MK-8408 administered as a PMF1 tablet by means of AUC0-*, AUClast, AUC0-24, Cmax, C24, tmax, and t* under fed conditions, following a high fat meal. 2. To…

A Study to Evaluate the Comparative Bioavailability of One Tablet of 480 mg MK-8228 and Two Tablets of 240 mg MK-8228 Under Fasted Conditions in Healthy Subjects

- To compare the primary pharmacokinetic parameters AUC0-last, AUC0-*, and Cmax of MK-8228 after single dose administration of one tablet of 480 mg MK-8228 (test) and two tablets of 240 mg MK-8228 (reference) under fasting conditions.- To compare…

Pharmacokinetic study of the HCV protease inhibitor bocePRevir and the proton pump inhibitor OMeprazOle (PROMO)

Primary objectiveTo determine the effect of multiple dose OME on the pharmacokinetics (AUC0-8h, Cmax, C8h) of BOC.Secondary objectives:To determine the effect of steady state BOC on the pharmacokinetics (AUC0-8h, Cmax, C8h) of multiple dose OME.To…

Pharmacokinetic study of the HCV protease inhibitor bO-cePrevir and the HIV integrase inhibitor rALtegravir (OPAL)

Primary objectiveTo determine the effect of steady state boceprevir on the pharmacokinetics (AUC0-12h, Cmax, C12h) of a single dose raltegravir.Secondary objectives:To determine the effect of a single dose raltegravir on the pharmacokinetics (AUC0-…

An Open-Label Two-Way Drug-Drug Interaction Study to Assess the Effect of Tenofovir on the Pharmacokinetics of BMS-790052 and the Effect of BMS-790052 on the Pharmacokinetics of Tenofovir in Healthy Subjects

The purpose of the study is to investigate the effect of multiple oral doses of Tenofovir on how quickly and to what extent BMS-790052 is absorbed and eliminated from the body and the effect of multiple oral doses of BMS-790052 on how quickly and to…

The Effect of Rosuvastatin on Immune Activation Markers in Treatment-naïve HIV-Positive Patients; a Randomized Placebo-Controlled Trial

Primary Objective: to investigate the effect of rosuvastatin 20 mg qd on subsequent immune activation markers in treatment-naïve HIV-patients: circulating LPS (LAL assay), TLR mRNA expression in whole blood, circulating IL-6, D-dimer, hsCRP, CD38…

Experimental Human Rhinovirus Infection, a randomized placebo-controlled pilot study

Our primary objective is to set up the Human Rhinovirus (HRV)-model in our centre, using HRV serotype 16 (HRV-16). Secondary objectives:1. To determine the incubation period of HRV-16 infection.2. To determine the effects of HRV-16 infection on cold…

Maraviroc Abacavir STudy - effect on Endothelial Recovery

First, to assess the effect of addition of maraviroc to an abacavir-containing regimen on endothelial function; second, to assess the effect of this intervention on markers of immune activation and chronic inflammation.

Pharmacokinetic Interaction between Antiretroviral and Cytotoxic therapy in HIV-infected patients - a pilot study

1º Is there a significant difference of more than 10% in the pharmacokinetic parameter AUC of the investigated antineoplastic drugs (as a surrogate parameter for the efficacy) in the presence and absence of NNRTIs and/or PIs?2º Are there clinically…

Pharmacokinetic drug interaction study between rAltegraVIr and ATORvastatin (AVIATOR).

Primary objective:To assess the effect of multiple dose atorvastatin on the steady state pharmacokinetics of raltegravir and vice versa by intrasubject comparison in healthy subjects.• The comparison of steady state raltegravir (400 mg BID for 7…

A Three Part Study Evaluating the Pharmacokinetics of Intravenous (IV) Danoprevir (DNV)/Oral Low Dose Ritonavir (RTV), a Drug-Drug Interaction Study Between IV DNV/Oral Low Dose RTV and Oral Cyclosporine, and the Absolute Bioavailability of IV DNV as Compared to DNV Tablets Together With Oral Low Dose RTV in Healthy Adult Volunteers

The purpose of the study is to investigate how quickly Danoprevir is absorbed and the extent of absorption and elimination from the body (this is called pharmacokinetics and bioavailability) when it is administered intravenously (IV) or orally alone…

The pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of Lopimune vs. the branded product

Primary objective: To determine the pharmacokinetic profile of lopinavir and ritonavir in two differ-ent co-formulations (Lopimune granules and Lopimune tablets) after single-dose in HIV-negative, healthy adult subjects, and to compare this to the…

The effect of FOsamprenavir/Ritonavir on the pharmacokinetics of a single-dose of the antipsychotic agent olanZApine (FORZA)

Primary objective: To evaluate the influence of fosamprenavir/ritonavir on single-dose pharmacokinetics of olanzapine in healthy volunteersSecondary objective: To evaluate the safety of fosamprenavir/ritonavir combined with single-dose olanzapine in…

Phase I, open-label, randomized, crossover trial in healthy adults to compare the oral bioavailability of 3 concept pediatric formulations of TMC278 (solution, suspension, granules) to that of the adult 25 mg Phase III tablet formulation, and to assess the food effect for each concept formulation.

This study involves research and the objective of this study is to evaluate how much and how fast TMC278 is absorbed into the body after administration as these concept pediatric formulations compared to when administered as the 25 mg TMC278 tablet…

The influence of GINkGo biloba on the pharmacokinetics of the UGT substrate raltEgraviR (GINGER)

To determine the effect of chronic use of ginkgo biloba on the single-dose pharma-cokinetics (AUC0-inf, AUC0-12, Cmax, C12) of raltegravir 400mg in healthy volunteers.